Promising Results: RSV Vaccine for Infants Receives FDA Panel Recommendation for Approval

RSV Vaccine for Infants Receives Positive FDA Panel Recommendation

The Pfizer RSV vaccine has been recommended for approval in pregnant individuals by an FDA advisory panel.
Promising study results showed the experimental vaccine's effectiveness in protecting newborns from severe
respiratory illnesses associated with RSV.
The vaccine demonstrated efficacy against lower respiratory tract illnesses, including pneumonia and bronchiolitis,
in infants up to six months old. While concerns were raised about potential risks, the FDA often follows the
recommendations of the advisory committee. If approved, the vaccine could provide crucial protection to infants and
become the world's first approved RSV vaccine."

Latest Posts